Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Therapy Name | Enavatuzumab |
Synonyms | |
Therapy Description |
Enavatuzumab (PDL 192) is a monoclonal antibody against tumor necrosis factor-like weak inducer of apoptosis receptor (TWEAKR) that activates innate anti-tumor immune response (PMID: 29075649, PMID: 29054986). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Enavatuzumab | PDL 192 | Enavatuzumab (PDL 192) is a monoclonal antibody against tumor necrosis factor-like weak inducer of apoptosis receptor (TWEAKR) that activates innate anti-tumor immune response (PMID: 29075649, PMID: 29054986). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|